This is a working overview of NR1D1, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-26. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
=== Types === 2-keto compounds: clorazepate, diazepam, flurazepam, halazepam, prazepam, and others 3-hydroxy compounds: lorazepam, lormetazepam, oxazepam, temazepam 7-nitro compounds: clonazepam, flunitrazepam, nimetazepam, nitrazepam Triazolo compounds: adinazolam, alprazolam, estazolam, triazolam Imidazo compounds: climazolam, loprazolam, midazolam 1,5-benzodiazepines: clobazam
== January 19, 1982 (Tuesday) == The explosion of a boiler at the Star Elementary School in Spencer, Oklahoma, killed five children and a schoolteacher while they were at lunch in the school cafeteria, and injured 35 others. The Iran Liberation Front was founded by former Prime Minister Ali Amini and other Iranians in exile in Paris with the goal of restoring the Iranian monarchy (abolished in 1979) and placing former Crown Prince Reza Pahlavi, son of Mohammad Reza Pahlavi, last Shah of Iran, as head of state. Funded by the American CIA, the Front would achieve its greatest success on September 5, 1986, by overriding all Iranian television channels to deliver an 11-minute speech from Reza Pahlavi. The Coca-Cola Company announced its plans to purchase ownership of the filmmaker Columbia Pictures. Born: Juan García Postigo, Spanish actor and model known for winning the 2007 Mister World male beauty competition; in Málaga Died: Semyon Tsvigun, 64, Soviet Ukrainian intelligence agent, deputy to Soviet KGB Director (and future Soviet Communist Party leader Yuri Andropov), died from an apparent suicide. Leopold Trepper, 77, Polish-born Soviet anti-Fascist espionage leader of the Red Orchestra spy network, later imprisoned in the Soviet Union after being accused of cooperation with Germany as a prisoner of war, died in Israel, where he had been allowed to emigrate in 1973. Marya Zaturenska, 80, Russian-born American lyric poet and 1938 Pulitzer Prize winner.
=== Trends observed by Vigitel === Since its implementation in 2006, Vigitel has collected information from more than 833,000 Brazilian adults, making it one of the largest continuous surveillance systems for chronic disease risk factors in Latin America. The surveillance system has documented parallel increases in obesity, diabetes, and other chronic disease risk factors. Vigitel findings are frequently used by researchers, public health agencies, and policymakers to monitor population health trends in Brazil.
Sources: en.wikipedia.org
== Awards and honors == Arthur C. Cope Scholar Award (2024) from the American Chemical Society for his foundational contributions to organic chemistry. Cathay Award (2024) from the Chinese Peptide Society for his work in peptide science. Max Bergmann Kreis Gold Medal (2011) for outstanding contributions in peptide chemistry. Vincent du Vigneaud Award (2010) from the American Peptide Society.
Fish maw (also fish sound) is the swim bladder of a fish, eaten as offal. Typically dried or fried but also cooked from fresh, fish maw is largely collagen. It is a traditional food in cuisines dominated by fishing, and a particular delicacy in Chinese cuisine—one of the four sea delicacies—as well as a valued ingredient in traditional Chinese medicine. The modern demand for fish maw from Pacific Asia supports wildlife trade worldwide for quality fish maw, which has in turn led to wildlife smuggling and poaching.
The incidence of side effects with doxepin and its safety at these doses was similar to that of placebo in clinical trials; the most frequent side effects were headache and somnolence/sedation, both with an incidence of less than 5%. Other side effects sometimes associated with antihistamines, including daytime sedation, increased appetite, and weight gain, all were not observed. Clinical evidence of H1 receptor antagonists and TCAs for the treatment insomnia shows mixed effectiveness and is limited in its quality due to weaknesses like small sample sizes and poor generalizability. However, doxepin is a unique and notable exception; it has been well-studied in the treatment of insomnia and shows consistent benefits with excellent tolerability and safety. Aside from diphenhydramine and doxylamine, which have historical approval as hypnotics, doxepin is the only H1 receptor antagonist that is specifically approved for the treatment of insomnia in the United States. The effect sizes of very low-dose doxepin in the treatment of insomnia range from small to medium. These include subjective and objective measures of sleep maintenance, sleep duration, and sleep efficiency. Conversely, very low-dose doxepin shows relatively weak effects on sleep initiation and does not significantly separate from placebo on this measure. This is in contrast to benzodiazepines and nonbenzodiazepine (Z-drug) hypnotics, which are additionally effective in improving sleep onset latency.
Sources: en.wikipedia.org
Military deployments subsequently became commonplace and in some respects were counterproductive for the regime. Operation Palmiet, for example, though it temporarily quelled unrest in the occupied townships, was accompanied by outbreaks of violence in townships on the East and West Rand and others in the Cape Province around Port Elizabeth and Grahamstown. Almost immediately after troops completed their phased withdrawal from the Vaal on 24 October, a crowd of some 2,000 residents gathered in Sebokeng to confront the remaining police contingents, starting a fresh round of street fighting, while more than 70,000 children in the area launched an impromptu school boycott. The military were forced to return to the area on 31 October. According to Thula Simpson:In the following months this pattern was witnessed repeatedly: as the security forces deployed into a particular township, violent protest flared elsewhere; as they withdrew, unrest resumed where they had been. The floundering response of the security forces, resembling a fire engine racing repeatedly to the wrong fire, only fanned the flames of insurrection. Furthermore, these events, transmitted worldwide by an international press corps that had virtually unfettered access to the country at the time, communicated the message that government's writ in black areas only ran because of the huge military superiority the security forces enjoyed over virtually defenceless township inhabitants.
microbody Any of a diverse class of small membrane-bound organelles or vesicles found in the cells of many eukaryotes, especially plants and animals, usually having some specific metabolic function and occurring in great numbers in certain specialized cell types. Peroxisomes, glyoxysomes, glycosomes, and hydrogenosomes are often considered microbodies.
In a 1951 letter to the publisher Milton Waldman (1895–1976), Tolkien wrote about his intentions to create a "body of more or less connected legend", of which "[t]he cycles should be linked to a majestic whole, and yet leave scope for other minds and hands, wielding paint and music and drama". The hands and minds of many artists have indeed been inspired by Tolkien's legends. Personally known to him were Pauline Baynes (Tolkien's favourite illustrator of The Adventures of Tom Bombadil and Farmer Giles of Ham) and Donald Swann (who set the music to The Road Goes Ever On). Queen Margrethe II of Denmark created illustrations to The Lord of the Rings in the early 1970s. She sent them to Tolkien, who was struck by the similarity they bore in style to his own drawings. Tolkien was not implacably opposed to the idea of a dramatic adaptation, however, and sold the film, stage and merchandise rights of The Hobbit and The Lord of the Rings to United Artists in 1968. United Artists never made a film, although the director John Boorman was planning a live-action film in the early 1970s. In 1976 the rights were sold to Tolkien Enterprises, a division of the Saul Zaentz Company, and the first film adaptation of The Lord of the Rings was released in 1978 as an animated rotoscoping film directed by Ralph Bakshi with screenplay by the fantasy writer Peter S. Beagle. It covered only the first half of the story of The Lord of the Rings.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.